{'fraction_non_alphanumeric': 0.019625334522747548, 'fraction_numerical': 0.01159678858162355, 'mean_word_length': 4.905263157894737, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Evaluation of the efficacy and safety of Dolocox in patients with nonspecific back].

OBJECTIVE
To assess the dynamics of pain syndrome in patients receiving Dolocox for nonspecific back pain (NBS) in routine outpatient practice, the safety of treatment and satisfaction with its results of the doctor and patient.


MATERIAL AND METHODS
The study included 70 patients who received standard therapy for NBS for 14 days. On days 1, 10 and 14, the effects were evaluated using a visual analog pain scale, the Rolland-Maurice scale, FTF test, clinical impression scales and subjective evaluation of the effectiveness of therapy.


RESULTS
The results of the study demonstrated comparable indicators of the dynamics of pain syndrome, the level of pain intensity reduction, the tolerability of treatment, as well as a subjective assessment of the effectiveness of therapy on the 10th and 14th day of therapy. There were no serious adverse events during treatment.


CONCLUSION
The results obtained allow us to recommend short-term use of Dolocox to reduce the risk of potential side effects and increase adherence to therapy.